



For more information:
Contact LAUNCHfn
Karen Rands
678-222-3473
Karen@launchfn.com

**MEDICAL INFORMATION
SYSTEMS TECHNOLOGY,
LLC**

**Managing Hypertension in
Pregnant Women**

www.misttechnologies.com

**Industry: Life sciences and
biotechnology**

Management:
CEO Marc R. Solochek
CMO Dr. David Chaffin

Board of Managers:
Dr. Howard Aulick
Dr. David Chaffin
Thomas L. Pressman
Paul J. Mayer
Marc R. Solochek

Projected revenues:
2007-13.2 M
2008-43.4 M
2009-69.8 M

Current debt:
Founders-250K

Previous investment:
Founders-200K
Seed-150K

Financing sought:
\$3 million in debt and equity

Use of proceeds:
Marketing organization,
expanded clinicals, version
2.0

Business Description: MIST owns patent pending software which when used in conjunction with impedance cardiography will eliminate the severe consequences associated with premature births due to preeclampsia. The MIST test is low cost, non-invasive and easy to administer. It has been successfully used for the past three years resulting in a 50% reduction in preeclampsia, a total elimination of severe premature births, a 25% extension of gestational age to 37+ weeks and zero infant mortalities.

Unique Value Proposition:

Preeclampsia affects up to 400,000 pregnant women each year
Preeclampsia a leading cause of infant and maternal mortality
Preeclampsia during pregnancy currently consigns expectant mothers to bed rest, many times in hospitals, with the resulting loss of income, increased medical expenses and emotional distress.
Preeclampsia related premature births cost third party payers over \$19 billion annually.

**THE APPLICATION OF MIST'S SOFTWARE WITH IMPEDANCE CARDIOGRAPHY
CAN ELIMINATE ALL OF THESE PROBLEMS AND COSTS**

Key Success Factors:

- Retention of top medical device marketing leader
- Successful completion of clinical tests to further publicize MIST methodology
- Entry to key hospital facilities (280 major and 425 medium) which account for approximately 75% of all deliveries in the US
- Maintaining and expanding business relationship with CardioDynamics ("CDIC"), the largest supplier of impedance cardiography machines in the US

Key Risk Factors:

- Acceptance of MIST treatment protocol by medical community
- Potential need for FDA approval slowing marketing effort

MILESTONES:

- Fully tested product ready to market
- Patent pending (patent application published by U S Patent Office in September 2006)
- Successful use of software for three years in over 400 deliveries
- 3 year supply and distribution agreement with CDIC executed
- Nearly \$500K committed already

Preferred Funding Structure:

100 investment units costing \$30K per unit comprised of \$20,000 in 8.6% interest, 7-year bonds with mandatory prepayment and 10 membership units (0.2%).

Exit strategy:

Sale to publicly traded medical equipment, medical services or medical software supplier at a discounted public multiple (currently averaging 42 times income and 30 times operating cash flow)

Documents available:

Private Placement Memorandum as amended by Revised Business Plan dated January 11, 2007, Power Point, Organization Agreement, business plan